Acousia Therapeutics
Germany - TübingenBiotechnology
Focus: Acousia Therapeutics is a German biotech company focused on small-molecule therapeutics for hearing loss, operating as a public company since 2012. The company has a highly specialized pipeline concentrated on cisplatin-induced hearing damage, a significant unmet medical need in oncology.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Acousia Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Acousia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
bimokalner
Cisplatin-induced Hearing LossClinical Trials (1)
NCT06521190ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin
Phase 2Help build intelligence for Acousia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.